Drug Profile
N 11005
Alternative Names: N-11005Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator INNOPHARMAX
- Class Antihyperglycaemics; Insulins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Diabetes-mellitus(In volunteers, In adults) in China (PO)
- 14 Aug 2020 Beijing Hospital completes a phase I pharmacokinetics, pharmacodynamics and safety trial in Healthy volunteers in China in August 2020 (NCT04975022)
- 10 Dec 2019 Phase-I clinical trials in Diabetes mellitus (In volunteers, In adults) in China (PO) in December 2019 (NCT04975022)